Sickle Cell Anemia

Sickle Cell Anemia: What It Is and Why the Right Care Plan Matters

Sickle cell anemia is an inherited blood disorder in which a genetic change alters haemoglobin, the protein inside red blood cells that carries oxygen. The altered haemoglobin makes red cells stiff, sticky and crescent-shaped. These cells break down too early, causing anaemia, and they can block small blood vessels, cutting off oxygen to tissues and triggering episodes of severe pain. The condition is present from birth and lasts for life, and it affects far more than a blood count: everyday energy, school and work, travel plans, pregnancy decisions, infection risk and long-term organ health can all be involved.

For many patients and families, the hardest part is the unpredictability. A child who seems well may suddenly develop fever or intense pain. An adult may manage well for months, then face repeated hospital admissions, exhaustion, or quiet damage to the lungs, kidneys, eyes, bones or brain. Between crises the disease can look stable while complications progress silently — which is why structured, long-term follow-up matters as much as treating any single episode.

People usually look for specialist care for practical reasons. They want a clearer diagnosis, better prevention of painful crises, a systematic review of organ complications, or an honest opinion about whether bone marrow transplantation is worth considering. Some patients have been treated for years yet still experience frequent vaso-occlusive crises. Others have developed stroke risk, acute chest syndrome, severe anaemia, leg ulcers, pulmonary hypertension, kidney problems or avascular necrosis, and they want these managed in one coordinated place rather than across disconnected clinics. Parents often look for a centre that can bring paediatric haematology, transfusion medicine, infection prevention, pain management, imaging and transplantation together under one roof.

Modern care for sickle cell anemia works towards three goals: preventing complications before they occur, treating acute problems safely and quickly, and identifying the patients who may benefit from potentially curative therapy. Not every patient needs the same treatment, and not every patient is a transplant candidate. The best results usually come from consistent monitoring, early response to warning signs and a long-term partnership with physicians who understand both the disease and the patient’s life circumstances.

What is sickle cell disease, and is it the same as sickle cell anemia?

Sickle cell disease (SCD) is the umbrella term for a group of inherited conditions in which red blood cells contain abnormal, sickling haemoglobin. Sickle cell anemia — usually meaning the HbSS genotype, in which a person inherits the sickle haemoglobin gene from both parents — is the most common and typically the more severe form. Other forms of SCD combine one sickle gene with a different haemoglobin variant, such as haemoglobin C or beta thalassaemia, and these can behave differently from HbSS disease.

If you have seen both terms used for the same patient, that is not necessarily an error. In everyday language, sickle cell, sickle cell anemia and sickle cell disease are often used interchangeably. In a clinic letter, the precise genotype matters, because it influences the expected pattern of complications, the intensity of monitoring and the treatment plan.

What causes sickle cell anemia?

Sickle cell anemia is caused by a change in the gene that codes for the beta chain of haemoglobin. The altered protein, called haemoglobin S, behaves normally when oxygen levels are high but clumps into rigid rods when oxygen is released to the tissues. This deforms the red cell into the characteristic sickle shape. The change is inherited: a person develops the disease when they receive a sickle gene from both parents. Someone who inherits only one copy has sickle cell trait — they carry the gene, usually without significant symptoms, but they can pass it on to their children. Because sickle cell anemia is a congenital disease, it cannot be acquired later in life and it cannot be prevented by lifestyle. What lifestyle and treatment can influence is how often the abnormal cells cause trouble.

Sickling worsens when the body is under stress. Dehydration, infection, fever, cold exposure, high altitude, low oxygen levels and physical exhaustion all encourage red cells to deform and stick together. This is why trigger management is a genuine part of treatment, not an afterthought.

What causes the anemia in sickle cell disease?

The anaemia in sickle cell disease is caused mainly by haemolysis: sickled red cells are fragile and are destroyed far earlier than healthy red cells. The bone marrow works hard to replace them, but it usually cannot keep pace, so the haemoglobin level settles below normal. The breakdown products of destroyed red cells also explain other familiar features of the disease, including jaundice, gallstones and dark urine. On top of this chronic baseline, the anaemia can worsen suddenly — for example when the spleen traps a large volume of blood, when a viral infection temporarily switches off red cell production, or during a severe crisis. Distinguishing a patient’s stable baseline from a dangerous drop is one of the everyday skills of sickle cell care, and it is a key reason why patients benefit from having their baseline values documented and available wherever they are treated.

How common is sickle cell anemia?

Sickle cell anemia is among the most common inherited blood disorders in the world. It occurs most frequently in people whose ancestry traces to sub-Saharan Africa, the Mediterranean region, the Middle East, India and parts of the Americas — broadly, regions where malaria is or was widespread, because carrying a single sickle gene offers some protection against severe malaria. As populations move, the disease is now diagnosed and managed on every continent, and many countries screen newborns for it as a matter of routine. The practical point for families is that sickle cell anemia is not rare or obscure: it is a well-studied condition with established, guideline-based care pathways, and the quality of long-term follow-up makes a real difference.

Sickle Cell Disease Symptoms

Sickle cell disease symptoms range from everyday fatigue to sudden, serious medical events, and they vary widely from one person to the next. Some patients have relatively infrequent crises; others experience repeated hospitalisations and progressive organ complications. Common features include:

• Episodes of severe pain in the bones, chest, back, abdomen or limbs
• Fatigue, reduced exercise tolerance and shortness of breath from chronic anaemia
• Jaundice — yellowing of the eyes and skin from red cell breakdown
• Swelling of the hands and feet in infants and young children (dactylitis)
• Recurrent infections, particularly in early childhood
• Delayed growth or puberty in children
• Headaches, vision changes or neurological symptoms
• Leg ulcers, typically around the ankles, in adolescents and adults

Because symptoms fluctuate, families sometimes underestimate the disease during quiet periods. A structured care plan takes both faces of the condition seriously: the acute crises that everyone notices, and the slow background processes — kidney stress, eye changes, bone damage, lung strain — that may cause no symptoms until they are advanced.

What are 5 symptoms of a sickle cell crisis?

A sickle cell crisis — also called a vaso-occlusive crisis — happens when sickled cells obstruct small blood vessels and trigger inflammation. Five symptoms that commonly mark a crisis are:

1. Sudden severe pain, most often in the bones, joints, back, chest or abdomen, which may build over hours
2. Fever, which can accompany a crisis or signal the infection that triggered it
3. Swelling and tenderness of the affected area — in young children, classically the hands and feet
4. Marked fatigue or paleness, reflecting a drop in haemoglobin below the patient’s usual baseline
5. Chest pain, cough or breathlessness, which raise concern for acute chest syndrome rather than a simple pain episode

Crises differ in severity. Some settle with rest, fluids and oral pain relief; others need hospital treatment with stronger analgesia, oxygen and close monitoring. Part of good long-term care is teaching each patient and family what their own typical crisis looks like, so that an unusual episode stands out.

What happens if a person has sickle cell anemia?

A person with sickle cell anemia lives with two parallel processes: chronic haemolytic anaemia, which is present every day, and intermittent vaso-occlusion, which arrives in episodes. Over years, repeated vessel blockage and inflammation can affect almost any organ. The spleen is often damaged early in childhood, which weakens the body’s defence against certain bacteria and explains the emphasis on vaccination and prompt evaluation of fever. The brain can be affected by overt or silent strokes. The lungs can develop acute chest syndrome in the short term and pulmonary hypertension in the long term. The kidneys, eyes, bones, skin and heart each have their characteristic complications. None of this is inevitable for a given individual — the course varies enormously — but it is the reason why sickle cell anemia is managed as a whole-body condition with scheduled screening, rather than as a series of isolated pain episodes.

How Sickle Cell Anemia Is Diagnosed

Diagnosis is usually confirmed with blood tests that identify the type and amount of haemoglobin present. These may include haemoglobin electrophoresis, high-performance haemoglobin analysis, a complete blood count, a reticulocyte count and genetic testing when needed. Many patients are diagnosed as newborns through screening programmes; others are diagnosed later, after repeated episodes of pain, anaemia or unexplained illness. In families with known sickle cell trait or disease, genetic counselling and testing may be recommended before pregnancy or in early childhood.

Confirming the genotype is only the first step. Physicians also establish the patient’s baseline: usual haemoglobin level, markers of red cell breakdown, kidney and liver function, inflammation, iron status and transfusion history. This baseline becomes the reference point for every future decision — it is what allows a doctor to recognise that today’s blood count is dangerously low for this particular patient, even if it would be unremarkable for another.

Because sickle cell anemia can affect many organs, a full assessment often extends beyond blood tests. Children may have transcranial Doppler ultrasound to evaluate stroke risk. Brain imaging is used when neurological symptoms are present, chest imaging during respiratory symptoms, and echocardiography when pulmonary hypertension is suspected. Oxygen saturation testing, urine studies for early kidney involvement, eye examination for retinopathy, bone imaging for avascular necrosis and assessment for sleep-related breathing problems may all have a place. For patients being considered for transplantation, HLA typing of siblings or other potential donors, infection screening, fertility counselling and organ function testing form part of the evaluation.

Who May Need Specialised Sickle Cell Anemia Care

Patients may need specialised care at different points in life. Some enter follow-up as newborns; others arrive as adults after years of fragmented treatment. Specialist input is particularly valuable for patients with frequent painful crises, acute chest syndrome, a previous stroke or high stroke risk, recurrent severe anaemia, multiple transfusions, iron overload, severe infections, kidney disease, pulmonary hypertension, pregnancy, planned surgery or a quality of life that remains poor despite standard treatment.

Children deserve a specific mention. Structured paediatric follow-up — vaccination, preventive antibiotics where guidelines indicate them, stroke-risk screening, growth monitoring and family education — can change the trajectory of the disease before serious complications occur. Adults, in turn, need a different emphasis: screening for heart, lung, kidney, eye and bone complications, management of chronic pain, planning around pregnancy or surgery, and honest discussion of long-term options. A programme that treats a nine-year-old and a thirty-nine-year-old identically is not treating either of them well.

Complications a Comprehensive Treatment Programme Addresses

The main indication for treatment is confirmed sickle cell anemia itself, but planning always considers disease severity, age, organ health, crisis frequency and prior treatment response. A comprehensive programme addresses both day-to-day control and urgent complications.

Painful vaso-occlusive crises occur when sickled cells obstruct small blood vessels and trigger inflammation. The mechanism differs from the acquired vessel narrowing seen in peripheral vascular diseases, but the consequence is similar: tissue starved of blood flow. Crises can be severe and call for rapid pain relief, hydration assessment, evaluation for infection or acute chest syndrome, and monitoring for further complications.

Chronic anaemia, caused by the shortened lifespan of sickled red cells, may lead to fatigue, exercise intolerance, rapid heartbeat, delayed growth in children and increased strain on the heart. Not all anaemia requires transfusion, but a severe or symptomatic drop below the patient’s baseline needs careful evaluation.

Acute chest syndrome is one of the most serious complications of the disease. It can resemble pneumonia, with chest pain, cough, fever, low oxygen levels and difficulty breathing, and it is treated as a medical emergency in every established guideline. Management may include antibiotics, oxygen, respiratory support and transfusion or exchange transfusion when appropriate.

Stroke prevention and treatment are central in paediatric sickle cell care. Children found to have elevated stroke risk may need regular transfusion therapy and neurological monitoring. Adults can also develop silent or overt brain injury and warrant evaluation when they experience headaches, weakness, speech changes, seizures or cognitive concerns.

Other indications include splenic complications, recurrent infections, gallstones, leg ulcers, priapism, kidney disease, retinopathy, avascular necrosis of the hip or shoulder, pulmonary hypertension, pregnancy-related risks and the consequences of repeated transfusion, particularly iron overload and antibody formation. For selected patients with severe disease or high-risk complications, evaluation for bone marrow transplantation is an important part of the plan.

How Sickle Cell Anemia Treatment Is Performed

Treatment is not one medication or one procedure. It is a coordinated programme, and its components are chosen for each patient. The main elements are described below.

Initial Evaluation and Treatment Planning

Care begins with a detailed medical review. The haematology team evaluates the diagnosis, crisis frequency, transfusion history, medications, infections, hospitalisations, surgical history, organ complications and family history. Previous blood tests, haemoglobin analysis, imaging, discharge summaries and transfusion records are all useful — they let the team see the patient’s real trajectory rather than a single snapshot, and they help identify which consultations and tests will actually be needed.

During the first visit, physicians assess current symptoms, baseline pain, growth and development in children, pregnancy plans when relevant, vaccination status and infection history. Laboratory tests establish anaemia severity, red cell production, haemolysis, inflammation, kidney and liver function, iron burden and the blood group profile. If transfusion is likely, extended blood group matching and antibody screening are performed to reduce the risk of transfusion reactions later on.

A personalised plan is then created. For some patients the priority is prevention of crises and organ damage; for others it is urgent treatment of a complication or a formal transplant evaluation. Complex cases may be discussed across haematology, paediatrics, transfusion medicine, infectious disease, cardiology, pulmonology, nephrology, neurology, ophthalmology, orthopaedics, pain medicine, intensive care and transplant medicine, so that the plan reflects more than one perspective.

Preventive Medical Treatment

Many patients benefit from medication that reduces sickling, inflammation or crisis frequency. Hydroxyurea is commonly used in sickle cell anemia because it can increase fetal haemoglobin, which helps red cells stay more flexible; it requires regular blood count monitoring and dose adjustment by the treating haematologist. Other disease-modifying medicines may be considered depending on age, availability, prior response and the patient’s clinical profile. Any change to a medication plan belongs to the treating doctor, made against that patient’s laboratory results and history.

Preventive care also includes folic acid when indicated, vaccination against important pathogens, prompt evaluation of fever, and — in young children — antibiotic prophylaxis according to paediatric guidelines, often planned with input from an infectious diseases team. Patients receive practical education: hydration habits, avoiding temperature extremes, recognising the early pattern of their own crises, preparing for air travel and pacing exertion at altitude. These measures do not replace medical therapy, but they remove avoidable triggers, and over years that adds up.

Managing a Sickle Cell Crisis

When a sickle cell crisis occurs, the first priority is to relieve pain and check for complications. Pain may be treated with non-opioid and opioid medication depending on severity, previous response and safety considerations. The team evaluates hydration status, oxygen levels, fever, chest symptoms and neurological signs, and uses laboratory tests and imaging to look for infection, acute chest syndrome, a dangerous fall in haemoglobin or organ stress.

Good crisis care is not simply giving pain medication. It involves monitoring, reassessment, prevention of under-treatment, avoidance of excessive sedation, respiratory support where needed and a safe discharge plan. Some patients need inpatient care; others can be treated and observed without a prolonged admission if symptoms improve and no dangerous complication is identified. Patients with sickle cell anemia often know their disease well, and a care team that listens to that experience usually manages the crisis better.

Transfusion and Exchange Transfusion

Transfusion may be used when oxygen delivery is dangerously reduced, before certain operations, during acute chest syndrome, for stroke prevention or after specific complications. In a simple transfusion, donor red cells are given to raise the blood’s oxygen-carrying capacity. In an exchange transfusion, some of the patient’s sickled red cells are removed while donor cells are infused. This rapidly lowers the proportion of sickle haemoglobin without thickening the blood as much as repeated simple transfusions might — a meaningful advantage in selected emergencies and in long-term prevention programmes.

The technology behind transfusion care includes automated apheresis systems for exchange transfusion, advanced blood bank testing, extended antigen matching and antibody screening. Repeated transfusion carries known costs to the body: iron accumulates, and antibodies can form that make future matching harder. Patients on regular transfusion therefore need monitoring of iron levels, and some need iron chelation therapy to protect the liver, heart and endocrine organs. This is why transfusion decisions in sickle cell care are made deliberately, not by default.

Screening for Organ Complications

Because sickle cell anemia can damage organs silently, routine screening is itself a form of treatment. Children may undergo transcranial Doppler ultrasound to assess blood flow patterns linked to stroke risk. Eye examinations can detect retinopathy before vision is threatened. Urine testing can reveal early kidney involvement. Echocardiography and lung evaluation are used when symptoms or findings suggest pulmonary hypertension or other cardiopulmonary problems.

Imaging — ultrasound, MRI, CT and X-ray — is chosen according to the clinical question. MRI can assess brain changes, bone infarction and avascular necrosis without radiation exposure; chest imaging is used for respiratory symptoms. The purpose of all of this is practical: to find complications early enough to adjust treatment before the damage becomes irreversible.

Bone Marrow Transplantation: Evaluation and Procedure

For selected patients, the pathway includes evaluation for haematopoietic stem cell transplantation — commonly called bone marrow transplantation. The process begins with the donor question: HLA typing is performed for siblings, and other donor sources may be considered where appropriate. Physicians also weigh disease severity, age, infection history, organ function, fertility considerations, psychological readiness and family support. Transplantation is a major therapy with important risks, including infection, graft-versus-host disease and effects on fertility or organ function, so patient selection is done carefully and the discussion of benefits and risks is detailed and honest.

If transplantation is recommended and the patient chooses to proceed, preparation typically includes conditioning treatment to make space in the bone marrow and reduce the risk of rejection. Donor stem cells are then infused through a vein, much like a blood transfusion. The cells travel to the bone marrow and begin producing new blood cells over time. During this period, patients need protective precautions and close monitoring for infection, bleeding, anaemia and graft function.

Hospitalisation length and recovery vary. Follow-up in the first months is intensive: frequent blood tests, antimicrobial medicines, and tracking of engraftment, immune recovery, medication levels, organ function and chimerism — the proportion of blood cells now derived from the donor. When transplantation succeeds, the new marrow produces red cells that do not sickle, which is why it remains the established treatment given with curative intent. It must always be weighed against its risks for the specific patient in front of the team.

Is there a cure for sickle cell anemia?

Bone marrow transplantation is the established treatment performed with curative intent, but it is not a universal answer: it requires a suitable donor, carries serious risks, and is generally reserved for patients whose disease burden justifies those risks. For everyone else, treatment is disease-modifying rather than curative — medication, transfusion strategies, infection prevention and organ screening that reduce crises and protect long-term health. Gene-based therapies are an area of active development in this field, and eligibility for any advanced option is an individual medical judgement, not a general rule. An honest care plan states plainly which category a given patient falls into and why.

Can you live a full life with sickle cell anemia?

Many people with sickle cell anemia study, work, travel, form families and live active adult lives, particularly where they have access to consistent, guideline-based care from childhood onwards. The condition is serious and can shorten life when complications go unmanaged, so the question is less about a single prediction and more about what shapes the outcome: early diagnosis, vaccination and infection care, stroke-risk screening in childhood, disease-modifying medication where indicated, sensible transfusion practice and regular organ monitoring. The disease also carries an emotional weight — chronic pain, unpredictability, repeated hospital visits — and a full life includes support for that dimension too, not only for the blood results.

Why Acting Early Matters

Sickle cell anemia can appear stable between crises while organ damage progresses quietly. Delayed care allows repeated vaso-occlusion, chronic inflammation and anaemia-related strain to affect the brain, lungs, kidneys, bones, eyes and heart. In children, missed screening can leave preventable neurological risk unaddressed. In adults, pulmonary hypertension, kidney disease or retinopathy may advance considerably before any symptom is obvious.

Acting early does not always mean aggressive treatment. It means timely diagnosis, consistent monitoring and choosing the right level of care before complications become harder to reverse: starting disease-modifying therapy when the treating doctor judges it indicated, taking fever seriously, identifying high stroke risk in childhood, managing transfusion complications properly and considering transplantation at the right point in the disease course rather than after severe damage has accumulated. Certain complications — acute chest syndrome and stroke among them — are treated as emergencies in clinical practice, which is exactly why structured education about a patient’s personal warning signs is a standard part of every good care plan.

Benefits of Treatment

The benefits of sickle cell anemia treatment depend on disease severity and the plan chosen, but the goals are practical and centred on the patient’s daily life.

Benefit	What It Means for You
Fewer or less severe pain crises	Preventive therapy and trigger management may reduce emergency visits and help you keep school, work and family life running more consistently.
Better protection of organs	Scheduled screening can detect early problems in the brain, kidneys, eyes, lungs, heart and bones, so treatment is adjusted before advanced damage develops.
Safer management of severe complications	Access to haematology, transfusion medicine, imaging and intensive care support guides treatment for acute chest syndrome, stroke risk, severe anaemia and infection.
Improved anaemia control	Medication, transfusion when genuinely needed and monitoring of haemolysis can improve fatigue, oxygen delivery and daily function in selected patients.
Evaluation for potentially curative therapy	Patients with significant disease can be assessed for bone marrow transplantation, including donor matching, risk evaluation and detailed counselling.

Recovery and Follow-Up Timeline

Recovery depends on what is being treated — a pain crisis, the start of preventive therapy, a transfusion programme or transplantation. The table below shows the typical shape of each phase.

Time Period	What Patients Can Expect
Day 1	Assessment focuses on pain level, oxygen status, fever, hydration, anaemia severity and warning signs. Testing and treatment are tailored to the immediate condition.
First week	Patients treated for a crisis may improve enough to continue recovery at home, while those with complications may need inpatient monitoring, transfusion, antibiotics or respiratory support.
First month	Follow-up may include medication adjustment, blood count monitoring, review of transfusion needs, organ screening and planning to prevent future crises.
After transplantation	Close monitoring for engraftment, infection, immune recovery and transplant-related complications. Follow-up is intensive in the first months and continues long term.
Longer term	Ongoing haematology care tracks organ health, medication response, growth and development in children, fertility or pregnancy considerations and quality of life.

Factors That Influence Outcomes

Outcomes in sickle cell anemia are shaped by both biology and the quality of care. The specific genotype, baseline haemoglobin, fetal haemoglobin level, crisis frequency, previous organ damage, infection history, age, pregnancy status and access to regular follow-up all matter. A patient who has already had a stroke, severe lung disease or kidney impairment needs a different plan from a child newly diagnosed through screening — and a plan built for one will not serve the other.

Adherence matters too. Hydroxyurea works only with regular use and laboratory monitoring. Transfusion programmes depend on careful scheduling, blood matching and iron surveillance. Vaccinations and fever plans must be kept current. Patients and families who understand their own warning signs are consistently better placed to stop complications from becoming severe.

For bone marrow transplantation, outcomes are affected by donor match quality, patient age, organ function before transplant, infection status, the conditioning approach, the graft source and post-transplant monitoring. A matched sibling donor is often associated with more favourable results than less closely matched sources, but every case needs individual assessment. The decision is never based only on whether transplantation is technically possible; it rests on whether the expected benefit justifies the risk for that particular patient at that particular point in their disease.

Emotional and social factors should not be overlooked. Chronic pain and repeated hospitalisation affect mental health, education, employment and family life. A good care plan treats pain as real, respects the patient’s own knowledge of their disease, and fits medical decisions to the realities of language, caregiving, travel and long-term follow-up at home.

How Acibadem Organises Sickle Cell Anemia Care

At Acibadem, care for sickle cell anemia is organised around evidence-based haematology, modern diagnostics and coordinated specialist input. Because the disease can touch many organs over a short period, haematologists work alongside paediatricians or adult medicine specialists, transfusion medicine teams, radiologists, neurologists, pulmonologists, cardiologists, nephrologists, ophthalmologists, orthopaedists, infectious disease physicians, pain specialists and transplant teams as each case requires. Complex decisions — a long-term transfusion programme, a difficult organ complication, a transplant evaluation — can be reviewed by specialist boards so that they reflect more than one perspective.

Diagnostic pathways support careful staging of the disease and its complications. Laboratory testing characterises haemoglobin type, anaemia severity, immune compatibility for transfusion and iron burden. Imaging and functional testing assess brain, lung, heart, kidney, eye and bone involvement. For patients being evaluated for transplantation, donor typing, organ function assessment, infection screening and transplant planning are coordinated through specialised teams. Technology is used practically rather than for show: automated exchange transfusion to reduce sickled cells rapidly in selected situations, advanced blood bank testing for better donor-recipient matching, MRI and ultrasound-based screening to find complications a routine examination would miss, and structured monitoring of engraftment and immune recovery after transplantation.

Plans are personalised rather than standardised around one option: a child with elevated stroke risk needs a different pathway from an adult with recurrent acute chest syndrome, and a patient without a transplant option still deserves rigorous preventive care and organ protection.

Because sickle cell anemia is lifelong, a responsible plan also looks past discharge. Documentation of baseline values, medication details, transfusion records, screening results, follow-up intervals and warning-sign education is prepared so that it can be shared with the patient’s local physician at home. For a condition managed over decades, that continuity is not an administrative nicety — it is part of the treatment.

Living Well With Sickle Cell Anemia

Sickle cell anemia can be painful, unpredictable and emotionally exhausting, but it is also one of the best-understood inherited conditions in medicine, with clear, established pathways for prevention, crisis care, transfusion and transplantation. With a proper evaluation, most complications can be anticipated earlier, crises can be managed more safely, and the genuine options — preventive medication, exchange transfusion programmes, transplant evaluation — can be weighed openly against their limits. The disease does not go away between crises, and neither should the plan: consistent follow-up, a documented baseline and a care team that knows the patient remain the most reliable tools this condition has.